NEW YORK, July 24 - Informatics company VizX labs intends to be cash-flow positive at the end of the year, according to an e-mail message from CEO and co-founder Thomas Ranken.
"We will develop the capacity to expand our company from new funding sources: earnings, investment, and debt," said Ranken.
VizX makes the GeneSifter.net gene expression-analysis software, a new version of which was launched earlier this month. Besides becoming cash-flow positive, Ranken said the company's "top priority" is to "build sales" for the software, which he said is responsible for the lion's share of the company's revenue.
Reached by telephone in VizX's Seattle, Wash., headquarters, Ranken said the firm intends to increase its sales staff and enter into new distribution deals.
VizX has been funded by angel investors up until now, Ranken said. He added the company is wrapping up a convertible-note round, and is talking to venture capitalists. "But ... the market is very tough."